EYPT (EyePoint Pharmaceuticals) Cash-to-Debt : 13.21 (As of Mar. 2025)

View and export this data going back to 2005. Start your Free Trial

What is EyePoint Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. EyePoint Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2025 was 13.21.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, EyePoint Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2025.

The historical rank and industry rank for EyePoint Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

EYPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43 Med: 5.01 Max: No Debt
Current: 13.21

During the past 13 years, EyePoint Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.43. And the median was 5.01.

EYPT's Cash-to-Debt is ranked better than
57.57% of 1466 companies
in the Biotechnology industry
Industry Median: 7.695 vs EYPT: 13.21

EyePoint Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for EyePoint Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

EyePoint Pharmaceuticals Cash-to-Debt Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

1.10

5.40

3.16

67.48

16.97

EyePoint Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash-to-Debt	Get a 7-Day Free Trial															64.74	12.03	11.58	16.97	13.21

Competitive Comparison of EyePoint Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

EyePoint Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

EyePoint Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	370.913	/	(0	+	21.858)
	=	16.97

EyePoint Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2025 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	318.194	/	(1.768	+	22.314)
	=	13.21

EyePoint Pharmaceuticals (NAS:EYPT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

EyePoint Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PV3B:Germany

Address

480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Executives

Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Goran Ando	director
Wendy F Dicicco	director
Nancy Lurker	director, officer: President and CEO	PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
David R Guyer	director	ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
David Scott Jones	officer: SVP & Chief Commercial Officer	C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
Dario A. Paggiarino	officer: Chief Medical Officer	4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Ye Liu	director	ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Michael Craig Pine	officer: Chief Corp Dev.&Strat. Officer	C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p.	10 percent owner	21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Anthony P Adamis	director	3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension	10 percent owner	56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston	officer: Chief Financial Officer	124 CHATHAM STREET, CHATHAM NJ 07928
John B. Landis	director	1700 KENT AVENUE, WEST LAFAYETTE IN 46906